• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

    11/12/24 2:40:35 PM ET
    $FONR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $FONR alert in real time by email
    FONAR 8-K
    false 0000355019 0000355019 2024-11-12 2024-11-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Act of 1934

     

    Date of Report (Date of earliest event reported): November 12, 2024

     

     

     

    FONAR CORPORATION

    ______________________________________________________

    (Exact name of registrant as specified in its charter)

      

    Delaware  0-10248  11-2464137
    (State or other jurisdiction of incorporation)  (Commission File Number)  (I.R.S. Employer Identification No.)
           
       110 Marcus Drive, Melville, New York 11747
    (631
    ) 694-2929
       
       (Address, including zip code, and telephone number of registrant's principal executive office)   

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    [ ] Written communications pursuant to Rule 425 under the Securities Act 17 CFR 230.425)

    [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

     

    Securities registered pursuant to Section 12(b) of the Act.

     Title of each class  Trading symbol(s)  Name of each exchange on which registered
    Common Stock, $.0001 par value  FONR  Nasdaq Stock Exchange

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). [ ]

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

    Item 2.02(a) Results of Operations and Financial Condition.

     

    We reported the results of operations and financial condition of the Company for the first Fiscal quarter of 2025 which ended September 30, 2024 in a press release dated November 12, 2024.

     

    Exhibits:

     

      99.1 Press Release dated November 12, 2024.  

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    FONAR CORPORATION

    (Registrant)

    -------------------------------------------

    By /s/ Timothy R. Damadian

    Timothy R. Damadian

    President and CEO

    Dated: November 12, 2024

    Get the next $FONR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FONR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $FONR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fonar Announces Fiscal 2025 Financial Results for 3rd Quarter and Nine-Month Period

      Net Income increased 25% to $3.1 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Income from Operations for the quarter ended March 31, 2025 decreased 2% to $3.7 million as compared to the quarter ended March 31, 2024. Diluted Net Income Per Common Share Available to Common Stockholders increased 37% to $0.37 per share for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024.Total Revenues-Net increased 6% to $27.2 million for the quarter ended March 31, 2025 as compared to the quarter ended March 31, 2024. Total Cash, Cash Equivalents and Short-Term Investments decreased 4% to $54.4 million at March 31, 2025 as compar

      5/15/25 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025

      MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.Cash and Cash Equivalents and Short-term Iinvestments decreased 5% to $53.7 million at December 31, 2024, versus the fiscal year ended June 30, 2024. Total Revenues-Net for the six-month period ended December 31, 2024, decreased by 3% to $49.9 million, and for the quarter ended December 31, 2024, decreased by 2% to $25.0

      2/18/25 7:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $FONR
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      11/14/24 12:27:58 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Fonar Corporation

      SC 13G - FONAR CORP (0000355019) (Subject)

      2/13/24 5:04:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Fonar Corporation (Amendment)

      SC 13G/A - FONAR CORP (0000355019) (Subject)

      2/13/24 4:05:17 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • FONAR Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - March 20, 2023) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that its board of directors appointed Jessica Maher as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, chairman, president and CEO of FONAR, said, "FONAR's primary source of income and growth is attributable to its diagnostic imaging management subsidiary, Health Management Company of America (HMCA). As a management company, HMCA bills and collects for all services rendered at HMCA-managed and HMCA-owned facilities. These facilities, all of them located in New York and Florida and coll

      3/20/23 11:37:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Board of Directors Appoints Independent Director

      Melville, New York--(Newsfile Corp. - November 23, 2021) - FONAR Corporation (NASDAQ:FONR), The Inventor of MR Scanning, today announced that on November 17, 2021, its board of directors appointed John Collins as a replacement independent director to a vacancy on the Company's board of directors and audit committee.Timothy Damadian, president and CEO of FONAR, said, "Our primary source of income and growth is attributable to FONAR's diagnostic imaging management subsidiary, Health Management Company of America (HMCA). Mr. Collins' extensive experience in dealing with insurance companies will be very helpful to HMCA. As a management company, HMCA bills and collects for all services rendered

      11/23/21 2:07:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Financials

    Live finance-specific insights

    See more
    • Fonar Announces Financial Results for the 1st Quarter of Fiscal 2025

      Total MRI scan volume at the HMCA-managed sites increased 5% to 53,054 scans for the quarter ending September 30, 2024 versus the corresponding quarter one year earlier. Cash and cash equivalents decreased 4% to $54.2 million at September 30, 2024 as compared to the fiscal year-ended June 30, 2024.Total Revenues - Net decreased by 3% to $25.0 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Income from Operations decreased 30% to $4.6 million for the quarter ended September 30, 2024 versus the corresponding quarter one year earlier.Net Income decreased 25% to $4.0 million for the quarter ended September 30, 2024 versus the corresponding quart

      11/12/24 7:00:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2023 3rd Quarter and Nine-Month Period

      Total MRI scan volume at the HMCA-managed sites increased 7% to 49,451 scans for the quarter ended March 31, 2023 versus the corresponding quarter one year earlier. For the nine-month period ended March 31, 2023, 139,339 scans were performed as compared to 140,650 for the corresponding nine-month period one year ago.Net Income increased 37% to $4.5 million for the quarter ended March 31, 2023 and decreased 27% to $9.9 million for the nine-month period ended March 31, 2023. Diluted Net Income Per Common Share Available to Common Stockholders increased 72% to $0.55 for the third fiscal quarter ended March 31, 2023 and decreased 19% to $1.16 for the nine-month period ended March 31, 2023. Tota

      5/15/23 4:05:00 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Announces Financial Results for Fiscal 2021 as Diluted EPS Increases 23%

      Total MRI scan volume at the HMCA-managed sites increased 7 % to 178,364 scans for the fiscal year ending June 30, 2021 as compared to the prior year.Total Revenues-Net increased by 5% to $89.9 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Income from Operations increased 25% to $17.1 million for the fiscal year ended June 30, 2021, versus the previous fiscal year.Net Income increased 17% to $13.7 million for the fiscal year ended June 30, 2021 versus the previous fiscal year.Diluted Net Income per Common Share increased 23% to $1.45 for the fiscal year ended June 30, 2021 versus the previous fiscal year. Book Value Per Share increased by 6% to $20.41 per s

      9/28/21 7:30:00 AM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Bonanni Luciano B bought $66,110 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $14.07), increasing direct ownership by 9% to 54,253 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:41:44 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4: Damadian Timothy Raymond bought $65,205 worth of FONAR CORPORATION COMMON STOCK (4,700 units at $13.87), increasing direct ownership by 12% to 42,700 units

      4 - FONAR CORP (0000355019) (Issuer)

      10/3/22 6:16:39 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $FONR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Fonar Corporation

      10-Q - FONAR CORP (0000355019) (Filer)

      5/15/25 2:14:54 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Fonar Corporation

      DEF 14A - FONAR CORP (0000355019) (Filer)

      4/7/25 3:03:53 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Fonar Corporation filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - FONAR CORP (0000355019) (Filer)

      2/19/25 4:16:47 PM ET
      $FONR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care